Navigation Links
Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
Date:6/9/2009

therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these r
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
4. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Pharmasset to Webcast an Investor Event from the AASLD Meeting
7. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
8. Pharmasset to Present at Two Upcoming Investor Conferences
9. Pharmasset to Present at Two Upcoming Investor Conferences
10. Pharmasset to Present at Deutsche Bank Healthcare Conference
11. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... low or very low birth weight may be at ... findings, which appear in Diabetes Care , may ... diabetes in African American populations, which has a high ... University,s Slone Epidemiology Center followed more than 21,000 women ... course of 16 years, analyzing characteristics such as birth ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Not only is ... can save them hundreds of health-care dollars a year, a ... a professor of public health sciences at Wake Forest Baptist ... overweight and obese type 2 diabetes patients. ... randomly assigned to either an intensive "lifestyle change program" focused ...
(Date:8/21/2014)... Dennis Thompson HealthDay ... -- A combination of therapy and antidepressants appears to ... new study reports. Four out of five people ... experienced full recovery when treated with cognitive therapy plus ... the combination didn,t work much better than drugs alone ...
(Date:8/21/2014)... A new study published this week ... disability associated with speech problems from 2001-02 to 2010-11 ... increase in disability associated with hearing problems. The data ... of children who are experiencing communication disorders, according to ... On a broader level, the new study, Changing ...
Breaking Medicine News(10 mins):Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Low birth weight linked to higher incidence of type 2 diabetes in African American women 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3
... simple questionnaire developed at the University of Oregon and ... time before or after a doctors appointment is credited ... 2-year-old children with mild developmental delays in a yearlong ... 53 of 78 referrals for special services or additional ...
... Partnership Identifies Healthcare Risks in 236 Countries and ... Detailed Destination-Specific Disease Information & Vital Profiles on Medical ... ... Combining their respective,strengths, MEDEX Global Group and Harvard Medical International ...
... Scientists Conclude Sweetener Is Safe Across Population ... ... A report published in the,September issue of Critical Reviews in ... scientific,information about aspartame and concludes that the low calorie sweetener is,safe. ...
... A history of maternal epilepsy and its associated treatment ... says a new study published in Epilepsia. Dr. Nina ... Institute of Public Health, Bergen, Norway, investigated the I.Q. ... epilepsy, and found a correlation between intelligence and the ...
... treat women with the breast cancer susceptibility gene BRCA1 ... of estrogen they believe fuels cancer growth. Yet they ... breast or ovarian cancer that might develop. That paradox ... estrogen is involved in cancer development and whether removal ...
... Heads New Department, NEW YORK, Sept. 11 ... Nick Childs, 38, an award-winning filmmaker,is joining the agency,s ... a new position. This marks the first in a,series ... the,transformation of Grey New York to the next level, ...
Cached Medicine News:Health News:Parental surveys boost diagnosis abilities of pediatricians 2Health News:Parental surveys boost diagnosis abilities of pediatricians 3Health News:MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers 2Health News:MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers 3Health News:New Expert Report Dispels Common Myths About Aspartame 2Health News:New Expert Report Dispels Common Myths About Aspartame 3Health News:New clues to breast cancer development in high-risk women 2Health News:New clues to breast cancer development in high-risk women 3Health News:New clues to breast cancer development in high-risk women 4Health News:Nick Childs Joins Grey New York as Director of Content Development 2
(Date:8/21/2014)... 2014 BreedIT Corp., (OTCQB: ... exclusive worldwide license holder and distributor of highly ... researchers, today is pleased to announce the formation ... Ltd, a leading Israeli medical Cannabis breeder. ... new breeds of medical Cannabis to meet the ...
(Date:8/21/2014)... FAIRFAX, Va. , Aug. 21, 2014 /PRNewswire/ ... real-time quality and Manufacturing Intelligence , today ... Intelligence Conference. The event will be held Oct. ... Mile, and is designed to showcase the necessity ... use of metrics and Manufacturing Intelligence to gain ...
(Date:8/21/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... and consideration payable in connection with its previously announced cash ... for (1) any and all of its 6.250% Senior Notes ... to a maximum amount of its 6.125% Senior Notes due ... due 2017 (collectively, the "Maximum Tender Offer Notes" and together ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... ST. LOUIS, Nov. 14, 2011 Express Scripts, Inc. ... wholly owned subsidiary, Aristotle Holding, Inc., a Delaware corporation ... of a benchmark amount.  The net proceeds from the ... the cash consideration payable to stockholders of Medco Health ...
... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced ... observations from previous clinical trials of Zerenex™ (ferric citrate) ... during the American Society of Nephrology (ASN) Kidney Week ... oral, ferric iron-based drug candidate, is currently in Phase ...
Cached Medicine Technology:Express Scripts, Inc. Launches Senior Notes Offering 2Express Scripts, Inc. Launches Senior Notes Offering 3Express Scripts, Inc. Launches Senior Notes Offering 4Express Scripts, Inc. Launches Senior Notes Offering 5Express Scripts, Inc. Launches Senior Notes Offering 6Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 2Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 3Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: